Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

IGYO18058 / Tesaro-FIRST / Richard Moore

Research Question:
Does the drug TSR-042 help the survival of patients with ovarian cancer?

Basic Study Information

Purpose:
Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian tumors provide several targets for treatment and maintenance of disease response. Given the unmet medical need of participants with advanced or metastatic ovarian cancer, this study design will enable investigators to provide participants with current SOC for ovarian cancer for the duration of the study. This is a global, multicenter, randomized, double-blind, controlled Phase 3 study that will primarily compare progressive survival rate of PD-L1 positive patients and also to compare progression-free survival (PFS) of all participants with Stage III or IV high-grade nonmucinous epithelial ovarian cancer treated with platinum-based combination therapy, dostarlimab, and niraparib to SOC platinum-based combination therapy. The currently recommended SOC therapy for the first line treatment of Stage III or IV ovarian cancer is the combination of paclitaxel and carboplatin, with or without concurrent and maintenance bevacizumab. Participants will receive SOC during the chemotherapy Run-In period (cycle 1) before randomization to study treatment (cycle 2). Concurrent bevacizumab use must be determined prior to randomization at cycle 2. Approximately 1228 participants will be enrolled into the study and the duration of the study will be approximately 78 months.

Location: University of Rochester Medical Center
Study Reference #: IGYO18058

Lead Researcher (Principal Investigator)

Lead Researcher:  Richard Moore

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search